L&S Knock-Out QBY 12.06.2024/ DE000LX3K4Q6 /
21/05/2024 09:21:42 | Chg.-0.01 | Bid09:21:42 | Ask09:21:42 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.52EUR | -1.89% | 0.52 Bid Size: - |
0.55 Ask Size: - |
Q.BEYOND AG NA O.N. | 0.30 EUR | 12/06/2024 | Call |
GlobeNewswire
09:15
HEALWELL AI’s Pentavere Partners with Sunnybrook and Successfully Demonstrates its AI Powered Clinic...
GlobeNewswire
07:30
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
02:25
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GlobeNewswire
02:15
West Coast Community Bancorp and 1st Capital Bancorp Announce Agreement to Merge
GlobeNewswire
20/05
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
GlobeNewswire
20/05
PowerUp Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders
GlobeNewswire
20/05
INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 2024
GlobeNewswire
20/05
Zoom Video Communications Reports Financial Results for the First Quarter of Fiscal Year 2025
GlobeNewswire
20/05
Equinix (EQIX) Faces Class Action, Multiple Regulatory Investigations Related to Manipulated Account...
Newsfile Corp
20/05
KPMG Upgrades GenAI Audit Assistant, Unveiling New Capabilities To Empower Its 9,000+ Audit Partners...
GlobeNewswire
20/05
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 Intern...
GlobeNewswire
20/05
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
20/05
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...